Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 8—August 2005


Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A4

Preexposure (seasonal) prophylaxis trials included in the analysis

Trial Age group, y Intervention (no. participants) Treatment duration
Hayden et al., 1999 (11) 18–65 Oseltamivir 75 mg 1×/d (520) 6 weeks
Oseltamivir 75 mg 2×/d (520)
Placebo (519)
Monto et al., 1999 (15) 18–69 Zanamivir 10 mg 1×/d (553) 4 weeks
Placebo (554)

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO